GS101 vs Dupixent® for Atopic Dermatitis
A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection
- Age
- 18 – 55
- Sex
- Male
- Trial phase
- Phase 1
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 294 (estimated)
- Sponsor
- Jiangsu Genscend Biopharmaceutical Co., Ltd · Industry
This trial is looking for healthy adult men in China to compare two treatments for atopic dermatitis. Participants will receive either the GS101 injection or Dupixent® and will be monitored for safety and how their bodies respond to the treatments.
You may be able to join if
- I am a healthy adult male
- I weigh between 55 and 85 kg
- My body mass index (BMI) is between 19 and 26
- I agree to use contraception with my partner
- I do not plan to donate sperm
- My health screenings show no significant issues
You may not be able to join if
- I have a history of certain diseases that could affect the study
- I have allergies to multiple drugs or foods
- I have a known allergy to certain monoclonal antibodies
- I tested positive for any infectious diseases
Summarized in plain language from this trial's official eligibility criteria. The full criteria are further down this page — only the research team can confirm whether you qualify.
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your EligibilityThis is a randomized, double-blind, three-arm, parallel-group study designed to demonstrate the similarity of the pharmacokinetics (PK), safety, and immunogenicity of GS101 injection compared with U.S. commercial Dupixent® and CN commercial Dupixent® in healthy adult participants in China. A total of 294 healthy male adult participants, with 98 participants per treatment group across 3 groups.
Loading trial locations…